Treatment Information

Cancer Monthly > Treatment Information
Back

Lung Cancer treatment details. Chemotherapy, Biologic therapy.

David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Los Angeles, CA
Treatments:Chemotherapy, Biologic therapyHospital:David Geffen School of Medicine at UCLA
Drugs:Journal:Link
Date:Aug 2014

Description:

Patients:
This phase 3 study involved non-small cell lung cancer patients who had received prior platinum-based chemotherapy and were divided into two separate treatment groups. Group A consisted of 628 patients with a median age of 62 years; 67% were male. Group B had 625 patients with a median age of 61 years; 66% were male.

Treatment:
Patients in group A received chemotherapy with docetaxel and biologic therapy with ramucirumab (a monoclonal antibody that blocks the VEGFR-2 protein).

Patients in group B received chemotherapy with docetaxel and a placebo.

Toxicities:
Treatment-related deaths due to hemorrhage, infection, cardiac events, respiratory problems, kidney failure and pulmonary embolism were reported for group A. Grade 3 or higher fatigue, mucosal inflammation, and diarrhea were also reported.

Treatment-related deaths due to hemorrhage, infection, cardiac events, respiratory problems, and stroke were reported for group B. Grade 3 or higher fatigue, shortness of breath, and vomiting were also reported.

Results:
The median overall survival rates for groups A and B were 10.5 and 9.1 months, respectively.

Support:
This study was supported by Eli Lilly.

Correspondence: Dr. Edward B Garon; email: [email protected]

Email Physician More Information


Back